Drug release kinetics from stent device-based delivery systems

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 2, 2008, Pages 118-125

  Tesfamariam, Belay ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Carrier vehicle; Drug delivery; Local vascular toxicity; Release kinetics; Restenosis; Stents

Indexed keywords

BIOMATERIAL; DRUG CARRIER; LACTIC ACID; METHACRYLIC ACID; PHOSPHORYLCHOLINE; POLY(ORTHO ESTER); POLYCAPROLACTONE; POLYMER; POLYURETHAN; RAPAMYCIN;

ARTERY WALL; BIODEGRADABLE IMPLANT; BLOOD VESSEL WALL; DRUG ABSORPTION; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG RESPONSE; ELUTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KINETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STENT; VASCULAR DISEASE;

ANIMALS; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 39749181623     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318158540f     Document Type: Review

References (49)

1. Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617-624.
2. Farb A, Weber OK, Kolodgie FD, et al. Morphological predictors of restenosis after coronary stenting in humans. Circulation. 2002;105:2974-2980.
3. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44:1373-1385.
4. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology. Drug-eluting stents: part I. Circulation. 2003;107:2274-2279.
5. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med. 2006;354:483-495.
6. Finkelstein A, McClean D, Kar S, et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation. 2003;107:777-784.
7. Bertrand OF, Sipehia R, Mongrain R, et al. Biocompatibility aspects of new stent technology. J Am Coll Cardiol. 1998;32:562-571.
8. Taylor AJ, Gorman PD, Kenwood B, et al. A comparison of four stent designs on arterial injury, cellular proliferation, neointima formation, and arterial dimensions in an experimental porcine model. Catheter Cardiovasc Interv. 2001;53:420-425.
9. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86:879-884.
10. Hwang CW, Wu D, Edelman ER. Physiologic transport forces govern drug distribution for stent-based delivery. Circulation. 2001;104:600-605.
11. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation. 2001;103:2816-2821.
12. Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol. 2005;46:253-260.
13. Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med. 1996;334:561-566.
14. Tamai H, Igaki, K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399-404.
15. Wood SC, Bushar G, Tesfamariam B. Inhibition of mammalian target of rapamycin modulates expression of adhesion molecules in endothelial cells. Toxicol Lett. 2006;165:242-249.
16. 1 arrest in human arterial smooth muscle cells. Cell Cycle. 2004;3:1050-1056.
17. Muldowney JA, Stringham JR, Levy SE, et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol. 2007;27:400-406.
18. 2 kinase activation. Circ Res. 2006;99:149-155.
19. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005;112:2002-2011.
20. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol. 2005;45:1574-1579.
21. Inoue T, Sata M, Hikichi Y, et al. Mobilization of CD34-positive bone marrow-derived cells after coronary stent implantation. Impact on restenosis. Circulation. 2007;115:553-561.
22. Blindt R, Vogt F, Astafieva I, et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J Am Coll Cardiol. 2006;47:1786-1795.
23. Ohtani K, Egashira K, Nakano K, et al. Stent-based local delivery of nuclear factor-κB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation. 2006;114:2773-2779.
24. Tesfamariam, B. Local vascular toxicokinetics of stent-based drug delivery. Toxicol Lett. 2007;168:93-102.
25. van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation. 1996;94:1690-1697.
26. Taylor MS, Daniels AU, Andriano KP, et al. Six bioabsorbable polymers: in vitro acute toxicity of accumulated degradation products. J Appl Biomater. 1994;5:151-157.
27. Lewis AL, Willis SL, Small SA, et al. Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo. Biomed Mater Eng. 2004;14:355-370.
28. Shastri VP. Non-degradable biocompatible polymers in medicine: past, present and future. Curr Pharm Biotechnol. 2003;4:331-337.
29. Virmani R, Guagliumi C, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation. 2004;109:701-705.
30. Ranade SV, Miller KM, Richard RE, et al. Physical characterization of controlled release of paclitaxel from the TAXUS Express drug eluting stent. J Biomed Mater Res. 2004;71A:625-634.
31. Balakrishnan B, Tzafriri AR, Seifert P, et al. Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation. 2005;111:2958-2965.
32. Vetrovec GW, Rizik D, Williard C, et al. Sirolimus PK trial: A pharmacokinetic study of the sirolimus-eluting Bx Velocity stent in patients with de novo coronary lesions. Catheter Cardiovasc Interv. 2006;67:32-37.
33. Wessely R, Hausleiter J, Michaelis C, et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol. 2005;4:748-753.
34. Levin AD, Vukmirovic N, Hwang CW, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA. 2004;101:9463-9467.
35. Hwang CW, Edelman ER. Arterial ultrastructure influences transport of locally delivered drugs. Circ Res. 2002;90:826-832.
36. Amidon GL, Lennernas, H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
37. Royce A, Li S, Weaver M, et al. In vivo and in vitro evaluation of three controlled release principles of 6-N-cyclohexyl-2′-O-methyladenosine. J Control Release. 2004;97:79-90.
38. Skelly JP, Shiu GF. In vitro/in vivo correlations in biopharmaceutics: scientific and regulatory implications. Eur J Drug Metab Pharmacokinet. 1993;18:121-129.
39. Virmani R, Kolodgie FD, Farb A, et al. Drug eluting stents: Are human and animal studies comparable. Heart. 2003;89:133-138.
40. Lowe HC, Schwartz RS, Mac Neill BD, et al. The porcine coronary model of in-stent restenosis: Current status in the era of drug eluting stents. Cathet Cardiovasc Intervent. 2003;60:515-523.
41. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202.
42. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056-1061.
43. Togni M, Raber L, Cocchia R, et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol. 2007;120:212-220.
44. Fuke S, Maekawa K, Kawamoto K, et al. Impaired endothelial vasomotor function after sirolimus-eluting stent implantation. Circ J. 2007;71:220-225.
45. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-1521.
46. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126-2130.
47. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47:2108-2111.
48. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-2591.
49. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.